SA516371613B1 - Cgrp صيغة قرص لمركبات نشطة تجاه - Google Patents
Cgrp صيغة قرص لمركبات نشطة تجاهInfo
- Publication number
- SA516371613B1 SA516371613B1 SA516371613A SA516371613A SA516371613B1 SA 516371613 B1 SA516371613 B1 SA 516371613B1 SA 516371613 A SA516371613 A SA 516371613A SA 516371613 A SA516371613 A SA 516371613A SA 516371613 B1 SA516371613 B1 SA 516371613B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- cgrp
- active compounds
- tablet formulation
- api
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000007916 tablet composition Substances 0.000 title 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000006104 solid solution Substances 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936019P | 2014-02-05 | 2014-02-05 | |
| US201462087366P | 2014-12-04 | 2014-12-04 | |
| PCT/US2015/013672 WO2015119848A1 (en) | 2014-02-05 | 2015-01-30 | Tablet formulation for cgrp-active compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA516371613B1 true SA516371613B1 (ar) | 2021-06-19 |
Family
ID=53778348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA516371613A SA516371613B1 (ar) | 2014-02-05 | 2016-08-04 | Cgrp صيغة قرص لمركبات نشطة تجاه |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10117836B2 (enExample) |
| EP (1) | EP3102564A4 (enExample) |
| JP (2) | JP6491669B2 (enExample) |
| KR (3) | KR102448369B1 (enExample) |
| CN (2) | CN112022818A (enExample) |
| AU (5) | AU2015214502B2 (enExample) |
| CA (1) | CA2937315A1 (enExample) |
| HK (1) | HK1232218A1 (enExample) |
| IL (1) | IL246828B (enExample) |
| MX (2) | MX383378B (enExample) |
| RU (2) | RU2019123406A (enExample) |
| SA (1) | SA516371613B1 (enExample) |
| WO (1) | WO2015119848A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI501968B (zh) * | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| CN112022818A (zh) | 2014-02-05 | 2020-12-04 | 默沙东公司 | Cgrp-活性化合物的片剂制剂 |
| US11717515B2 (en) | 2020-12-22 | 2023-08-08 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN105126111A (zh) * | 2015-09-30 | 2015-12-09 | 清华大学 | 提高索拉非尼生物利用度的制剂 |
| HUE064474T2 (hu) * | 2017-03-30 | 2024-03-28 | Merck Patent Gmbh | Gyógyászati kiszerelés |
| KR20200135465A (ko) * | 2018-03-25 | 2020-12-02 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | Cgrp 관련 장애를 위한 리메게판트 |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| RU2755571C1 (ru) * | 2020-06-09 | 2021-09-17 | Сергей Геннадьевич Каплунов | Способ изготовления гравюры на металле |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| MX2023005846A (es) * | 2020-11-19 | 2023-06-02 | Pfizer Ireland Pharmaceuticals | Composiciones para la administracion mejorada de los inhibidores de cgrp. |
| TW202241447A (zh) * | 2021-02-02 | 2022-11-01 | 瑞士商愛杜西亞製藥有限公司 | (4-甲基-2-[1,2,3]三唑-2-基-苯基)-[(r)-3-(3-[1,2,3]三唑-2-基-苄基)-嗎啉-4-基]-甲酮之結晶形式 |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| ATE509019T1 (de) | 2003-03-14 | 2011-05-15 | Merck Sharp & Dohme | Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten |
| CA2518830A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| DE602005020656D1 (de) | 2004-09-13 | 2010-05-27 | Merck Sharp & Dohme | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
| US7994325B2 (en) | 2005-03-14 | 2011-08-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| CN103735515A (zh) * | 2006-02-09 | 2014-04-23 | 默沙东公司 | Cetp抑制剂的聚合物制剂 |
| MX2008014353A (es) | 2006-05-09 | 2008-11-24 | Merck & Co Inc | Antagonistas de los receptores del peptido relacionado con el gen de calcitonina (cgrp) monociclicos sustituidos. |
| WO2008153849A1 (en) | 2007-06-05 | 2008-12-18 | Merck & Co., Inc. | Carboxamide heterocyclic cgrp receptor antagonists |
| MX2010003849A (es) | 2007-10-18 | 2010-04-27 | Boehringer Ingelheim Int | Antagonistas de cgrp. |
| EP2225237A2 (de) | 2007-11-22 | 2010-09-08 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| EP2249833B1 (en) * | 2008-02-05 | 2012-10-17 | Merck Sharp & Dohme Corp. | Prodrugs of cgrp receptor antagonist |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| PE20091778A1 (es) | 2008-04-15 | 2009-11-13 | Schering Corp | Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden |
| EP2413930A4 (en) * | 2009-03-31 | 2012-09-26 | Ligand Pharm Inc | ORAL FORMULATION OF ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS BASED ON DIPHENYLSULFONAMIDE TO TREAT HIGH BLOOD PRESSURE AND DIABETIC NEPHROPATHY |
| JP5449540B2 (ja) | 2009-06-05 | 2014-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US8883807B2 (en) | 2010-11-12 | 2014-11-11 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane CGRP receptor antagonists |
| TWI501968B (zh) * | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| US8895572B2 (en) | 2010-12-22 | 2014-11-25 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide CGRP receptor antagonists |
| US9067941B2 (en) | 2010-12-22 | 2015-06-30 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide CGRP receptor antagonists |
| CN103491964A (zh) * | 2011-03-08 | 2014-01-01 | 扎里卡斯药品有限公司 | 固体分散体制剂及其使用方法 |
| EP2685826B1 (en) | 2011-03-18 | 2016-02-03 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| CN103998461B (zh) | 2011-09-08 | 2018-02-02 | 科德克希思公司 | 用于合成取代的内酰胺的生物催化剂和方法 |
| AU2012322039C1 (en) | 2011-10-14 | 2021-04-29 | Array Biopharma Inc. | Solid dispersions of a Erb2 (HER2) inhibitor |
| EP3680240A1 (en) | 2012-03-14 | 2020-07-15 | Merck Sharp & Dohme Corp. | Asymmetric phase transfer catalysis |
| US9487523B2 (en) | 2012-03-14 | 2016-11-08 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| US9833488B2 (en) | 2012-04-25 | 2017-12-05 | Centric Research Institute | Sensitization composition and method of use |
| WO2013169567A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
| US9227972B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam CGRP receptor antagonists |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| WO2013169563A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Pyridine cgrp receptor antagonists |
| ES2769879T3 (es) | 2013-03-15 | 2020-06-29 | Tonix Pharma Holdings Ltd | Formulaciones eutécticas de clorhidrato de ciclobenzaprina y manitol |
| CN105531275B (zh) | 2013-09-16 | 2020-12-18 | 默沙东公司 | 用于cgrp受体拮抗剂的制剂 |
| CN112022818A (zh) | 2014-02-05 | 2020-12-04 | 默沙东公司 | Cgrp-活性化合物的片剂制剂 |
| EP3102188A4 (en) | 2014-02-05 | 2017-07-12 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| US11717515B2 (en) | 2020-12-22 | 2023-08-08 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20170189443A1 (en) | 2014-02-24 | 2017-07-06 | C. Lowell Parsons | Compositions and methods for treatment of diseases and conditions employing oral administration of sodium pentosan polysulfate and other pentosan polysulfate salts |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| US10022353B2 (en) | 2015-01-23 | 2018-07-17 | Grünenthal GmbH | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
| JP2018532728A (ja) | 2015-09-24 | 2018-11-08 | テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー | （持続性）外傷後頭痛の予防、治療および低減 |
| US20180092899A1 (en) | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
| RU2770066C2 (ru) | 2017-03-02 | 2022-04-14 | Бет Изрейэл Диконисс Медикал Сентер, Инк. | Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| US20190135927A1 (en) | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
| US20190374520A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20190374518A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| CA3133912A1 (en) | 2019-04-18 | 2020-10-22 | Allergan Sales, Llc | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| US20220340650A1 (en) | 2019-09-25 | 2022-10-27 | Abnijeet JAKATE | Combination therapy with cgrp antagonists |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
-
2015
- 2015-01-30 CN CN202010812438.5A patent/CN112022818A/zh active Pending
- 2015-01-30 KR KR1020167024025A patent/KR102448369B1/ko active Active
- 2015-01-30 HK HK17105813.5A patent/HK1232218A1/zh unknown
- 2015-01-30 WO PCT/US2015/013672 patent/WO2015119848A1/en not_active Ceased
- 2015-01-30 US US15/115,026 patent/US10117836B2/en active Active
- 2015-01-30 KR KR1020227032939A patent/KR20220136460A/ko not_active Ceased
- 2015-01-30 JP JP2016548023A patent/JP6491669B2/ja active Active
- 2015-01-30 AU AU2015214502A patent/AU2015214502B2/en active Active
- 2015-01-30 MX MX2016010169A patent/MX383378B/es unknown
- 2015-01-30 RU RU2019123406A patent/RU2019123406A/ru unknown
- 2015-01-30 CN CN201580006288.6A patent/CN105960397B/zh active Active
- 2015-01-30 RU RU2016135536A patent/RU2696578C1/ru active
- 2015-01-30 CA CA2937315A patent/CA2937315A1/en active Pending
- 2015-01-30 KR KR1020237022803A patent/KR20230107902A/ko not_active Ceased
- 2015-01-30 EP EP15746768.9A patent/EP3102564A4/en active Pending
-
2016
- 2016-07-18 IL IL246828A patent/IL246828B/en active IP Right Grant
- 2016-08-04 MX MX2021006790A patent/MX2021006790A/es unknown
- 2016-08-04 SA SA516371613A patent/SA516371613B1/ar unknown
-
2018
- 2018-11-02 US US16/178,641 patent/US20190209478A1/en not_active Abandoned
-
2019
- 2019-03-04 JP JP2019038349A patent/JP6666490B2/ja active Active
- 2019-09-06 AU AU2019226239A patent/AU2019226239B2/en active Active
-
2020
- 2020-12-03 US US17/110,398 patent/US11925709B2/en active Active
-
2021
- 2021-10-08 AU AU2021245229A patent/AU2021245229A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/137,925 patent/US20230248655A1/en not_active Abandoned
- 2023-10-30 AU AU2023258317A patent/AU2023258317A1/en not_active Abandoned
-
2025
- 2025-08-22 AU AU2025220825A patent/AU2025220825A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA516371613B1 (ar) | Cgrp صيغة قرص لمركبات نشطة تجاه | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| TW201613911A (en) | Heterocyclic compounds and uses thereof | |
| WO2016105564A8 (en) | Quinazoline derivatives used to treat hiv | |
| MX2021014663A (es) | Il-23a y tnf-alfa orientados y compuesto y sus usos. | |
| MX2017001379A (es) | Producto antiseptico, proceso para prepararlo y su uso. | |
| MY189913A (en) | Preparation containing tetracyclic compound at high dose | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| MX2017014035A (es) | Formas solidas novedosas. | |
| PH12016501807A1 (en) | Novel compounds | |
| EP4620458A3 (en) | Ribociclib tablet | |
| EA201591397A1 (ru) | Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| NZ731344A (en) | Hydroxyl purine compounds and applications thereof | |
| TN2016000490A1 (en) | Naphthyridinedione derivatives. | |
| PH12016501814A1 (en) | Inhibitors of the wnt signalling pathways | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| PH12016502272A1 (en) | Ceritinib formulation | |
| MX371158B (es) | Compuestos inhibidores de pde2. | |
| MX2016013439A (es) | Formas solidas de un compuesto farmaceuticamente activo. |